Global Hypercholesterolemia – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040
Global
Hypercholesterolemia Epidemiology Insights
Thelansis’s “Global
Hypercholesterolemia Epidemiology Insights and Forecast Report (Top 32 Markets)
– 2020 To 2040″ provides an analysis of disease burden, characterized by
disease definition, kidney biopsy cases, prevalence, incidence, diagnosed
cases, severity, comorbidities, and clinical manifestations. Potential patient
flow dynamics in disease burden are driven by shifts in demographic indicators
and their correlation with age and gender distribution over time. Changes in
the reported cases and long-term survival of patients may depend on diet,
lifestyle, comorbid conditions, and the availability of interventions or
therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific,
Africa, South / Latin America).
Hypercholesterolemia
Overview
Hypercholesterolemia, commonly
referred to as high cholesterol, is a metabolic disorder characterized by
elevated blood cholesterol levels. Cholesterol, a waxy, fat-like substance, is
essential for building healthy cells, but excessive amounts can lead to serious
health problems. The condition primarily involves an imbalance in lipoproteins,
particularly high levels of low-density lipoprotein (LDL), often termed “bad”
cholesterol, which contributes to plaque buildup in the arteries
(atherosclerosis), and sometimes low levels of high-density lipoprotein (HDL),
or “good” cholesterol, which helps remove excess cholesterol. While some cases
are inherited (familial hypercholesterolemia), most are influenced by lifestyle
factors such as a diet high in saturated and trans fats, lack of physical
activity, obesity, and smoking. Hypercholesterolemia is often asymptomatic
until significant atherosclerosis develops, which can manifest as chest pain,
heart attack, or stroke due to narrowed or blocked arteries.
Market
Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech
Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands,
Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United
Kingdom)
- Middle East (Saudi Arabia, UAE,
Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong
Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines,
Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa,
Morocco)
- South / Latin America (Argentina,
Brazil, Chile, Colombia, Mexico, Peru)
Deliverables format and updates*:
- Access to an interactive epidemiology
platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates,
customizations, epidemiologist support
- *As per Thelansis’s policy, we ensure
that we include all the recent updates before releasing the content.
Countries, subpopulations, and years of forecast can be customized as per
client requirements.
Key business questions answered:
- 20-year historical and forecast data
(2020–2040)
- Disease definition based on globally
accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage
by year and geography
- Detailed segmentation by age, gender,
subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g.,
staging/classification/severity)
- Insights driven by robust research
and estimates:
- Published literature (e.g.,
peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR
datasets
- Proprietary mathematical models
(e.g., incidence-survival model;
incidence- recurrence/progression-survival model)
Comments
Post a Comment